Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer.

CONCLUSIONS: Significant antitumor activity was observed in all the arms. Weekly nab-P with bevacizumab appeared to have the highest therapeutic index. However, sensory neuropathy was treatment limiting, which suggests that a 3 weeks on and 1 week off schedule should be explored. PMID: 23829890 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23829890?dopt=Abstract

Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA Tags: Clin Breast Cancer Source Type: research